Acquired/intratumoral mutation of KRAS during metastatic progression of colorectal carcinogenesis

Author：                

Publisher： Spandidos Publications

ISSN： 1792-1074

Source： Oncology Letters, Vol.3, Iss.3, 2012-01, pp. : 649-653

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival

By                                

Molecular and Clinical Oncology, Vol. 3, Iss. 5, 2015-01 ,pp. : 1053-1057

Science Publishers

Access to resources Recommend Favorite

Expression of E-cadherin and KRAS mutation may serve as biomarkers of cetuximab-based therapy in metastatic colorectal cancer

By                  

Oncology Letters, Vol. 5, Iss. 4, 2013-01 ,pp. : 1295-1300

Spandidos Publications

Access to resources Recommend Favorite

KRAS Mutation Analysis Prior to EGFR-Directed Therapy for Metastatic Colorectal Cancer: A Review and Cost Analysis

By  

Current Cancer Therapy Reviews, Vol. 6, Iss. 4, 2010-11 ,pp. : 256-261

Bentham Science Publishers

Access to resources Recommend Favorite

Differential prognosis of metastatic colorectal cancer patients post-progression to first-line triplet chemotherapy plus bevacizumab, FIr-B/FOx, according to second-line treatment and KRAS genotype

By            

International Journal of Oncology, Vol. 44, Iss. 1, 2014-01 ,pp. : 17-26

Spandidos Publications

Access to resources Recommend Favorite

KRAS mutational concordance between primary and metastatic colorectal adenocarcinoma

By          

Oncology Letters, Vol. 8, Iss. 4, 2014-01 ,pp. : 1422-1426

Spandidos Publications

Access to resources Recommend Favorite